Revenue
2022
2023
2024
2025
Atara Biotherapeutics, Inc. (ATRA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — | — | — | — | — | — | — | — | — |
| Research & development | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M | $244.7M | $216.1M | $167.5M | $81.2M | $56.5M | $41.6M | $14.4M | $4.3M |
| Operating expenses | — | — | — | $344.1M | $360.8M | $309.1M | $295.7M | $237.1M | $121.5M | $81.2M | $58.4M | $28.2M | $8.6M |
| Operating income | $35.9M | −$83.4M | −$276.0M | −$280.5M | −$340.5M | −$309.1M | −$295.7M | −$237.1M | −$121.5M | −$81.2M | −$58.4M | −$28.2M | −$8.6M |
| EBITDAderived | $38.0M | −$78.4M | −$271.2M | −$274.9M | −$331.1M | −$300.7M | −$288.6M | −$233.4M | −$120.6M | −$80.9M | −$58.4M | — | — |
| Net income | $32.7M | −$85.4M | −$276.1M | −$228.3M | −$340.1M | −$306.6M | −$291.0M | −$230.7M | −$119.5M | −$79.0M | −$57.2M | −$28.0M | −$8.8M |
| Basic EPSper diluted share | $2.61 | -$11.41 | -$65.19 | -$2.24 | -$3.63 | -$4.15 | -$5.67 | -$5.27 | -$4.00 | -$2.75 | — | — | — |
| Diluted EPSper diluted share | $2.57 | -$11.41 | -$65.19 | -$2.24 | -$3.63 | -$4.15 | -$5.67 | -$5.27 | -$4.00 | -$2.75 | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Nguyen AnhCoPresident and CEO | SellCommon Stock | 5.2K | $9.13 | $47.9K | 137.8K |
| May 18, 2026Form 4 | Grant-Huerta YaninaChief Accounting Officer | SellCommon Stock | 2.4K | $9.13 | $22.0K | 49.6K |
| May 7, 2026Form 4 | Panacea Innovation Ltd +1TenPercentOwner | SellCommon Stock · indirect | 313.4K | $10.10 | $3.17M | 1.01M |
| May 7, 2026Form 4 | EcoR1 Capital, LLCTenPercentOwner | BuyCommon Stock · indirect | 507.4K | $9.35 | $4.74M | 1.55M |
| Mar 2, 2026Form 4 | Grant-Huerta YaninaChief Accounting Officer | SellCommon Stock | 100 | $5.08 | $508.00 | 31.8K |